AbbVie (ABBV) Stock Forecast & Price Target

AbbVie's positive outlook is primarily driven by strong fiscal guidance, with management increasing projections for FY 2025 global sales to approximately $59.7 billion and non-GAAP EPS guidance to a range of $12.09-$12.29, reflecting healthy growth expectations. The company reported robust 1Q 2025 results, surpassing sales expectations at $13.34 billion, largely aided by key immunology and oncology products such as Skyrizi, Rinvoq, Imbruvica, and Venclexta, despite some declines in aesthetics performance. Additionally, the recent acquisitions in neuroscience and oncology, alongside the solid commercial performance of existing products, further strengthen AbbVie's growth trajectory and market position.

The analysis highlights several fundamental concerns contributing to a negative outlook on AbbVie's stock. Key risks include potential commercial execution failures of critical assets, ongoing competitive pressures particularly on their immunology and oncology products, and a weakened performance in their aesthetics segment due to macroeconomic challenges that may impact discretionary spending. Additionally, the anticipated erosion of Humira's market share from biosimilars in 2025, combined with pipeline delays and heightened operational costs, further complicates AbbVie's ability to meet long-term growth expectations.